storage temp.
−20°C
SMILES string
O=C1CNC(=S)N1c2ccccc2
InChI
1S/C9H8N2OS/c12-8-6-10-9(13)11(8)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)
InChI key
ZZRIQDWDJVLELF-UHFFFAOYSA-N
Gene Information
human ... CNR1(1268), CNR2(1269)
rat ... Faah(29347)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
法规信息
新产品
此项目有
Enzalutamide (Xtandi) for prostate cancer.
The Medical letter on drugs and therapeutics, 55(1411), e20-e20 (2013-03-08)
Sumanta K Pal et al.
Expert opinion on pharmacotherapy, 14(5), 679-685 (2013-02-28)
The FDA approval of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2005 marked a major milestone, as it was the first approved agent for this disease that demonstrated a survival advantage in Phase III assessment of this disease. Since
[The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].
Takeo Kosaka et al.
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 353-359 (2013-03-22)
Y S Ha et al.
Drugs of today (Barcelona, Spain : 1998), 49(1), 7-13 (2013-01-31)
Castration-resistant prostate cancer (CRPC) remains a major clinical challenge, given the mechanistic heterogeneity due to a complex signal transduction network. Enzalutamide (MDV-3100), recently approved by the U.S. Food and Drug Administration (FDA) at a dose of 160 mg/day for the
Manoj P Menon et al.
Current oncology reports, 15(2), 69-75 (2013-01-24)
Enzalutamide, formerly known as MDV3100, is an oral second generation androgen receptor (AR) inhibitor that was chosen from a screen of agents and shown in preclinical studies to have greater affinity for the AR than its predecessors without any agonistic
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持